国际妇产科学杂志

国际妇产科学杂志 ›› 2012, Vol. 39 ›› Issue (3): 250-253.

• 综述 • 上一篇    下一篇

肝素结合表皮生长因子在卵巢癌中的研究进展

汤小晗, 卢美松   

  1. 150001 哈尔滨医科大学附属第一医院妇产科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2012-06-15 发布日期:2012-06-15
  • 通讯作者: 卢美松

Progress in the Research of Heparin Binding-Epidermal Growth Factor in Ovarian Cancer

TANG Xiao-han，LU Mei-song   

  1. Department of Obstetrics and Gynecology，the First Hospital of Harbin Medical University，Harbin 150001，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2012-06-15 Online:2012-06-15
  • Contact: LU Mei-song

PDF (PC)

4807

摘要： 肝素结合表皮生长因子（HB-EGF）是表皮生长因子家族成员之一，可通过激活表皮生长因子受体发挥生物学效应。近来研究表明，HB-EGF在卵巢癌中高水平表达并在肿瘤的发生发展中起重要作用，因此成为极具潜力的卵巢癌治疗靶点。系统描述HB-EGF的特性及其特异性抑制剂白喉毒素突变体（CRM197）的研究现状，并讨论CRM197分别和膜型基质金属蛋白酶（MTl-MMP）抑制剂、去整合素-金属蛋白酶（ADAM）抑制剂及紫杉醇联合治疗卵巢癌的发展潜力。

关键词: 卵巢肿瘤, 表皮生长因子, 受体, 表皮生长因子, 肿瘤治疗方案, 肝素结合表皮生长因子

Abstract: Heparin binding-epidermal growth factor-like growth factor（HB-EGF），a member of the EGF family of growth factors，exerts its diverse biological activities through activation of the EGFR. Recently studies revealed HB-EGF expression was significantly elevated in ovarian cancer and it played a key role in the development of tumor，so HB-EGF was considered as a potential target for ovarian cancer therapy. The features of HB-EGF and the research progress of HB-EGF specific inhibitor CRM197 in therapy of ovarian cancer will be reviewed. We will also discuss the future direction for the development of therapeutic strategies targeting CRM197 and MTI-MMP inhibitor，ADAMs inhibitor，paclitaxel respectively.

Key words: Ovarian neoplasms, Epidermal growth factor, Receptor, epidermal growth factor, Antineoplastic protocols, Heparin binding-epidermal growth factor-like growth factor